\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThis MSCA lunchtime conversations session will focus on the future of democracy in the context of youth participation and political discourse needed to address young people’s values, interests and forms of engagement. It will look into the existing work and evidence on political participation of young people, further needs in terms of research and follow-up actions to better reach and engage young people.
The event gathers representatives from an MSCA Doctoral Network, the Commission’s Joint Research Centre (JRC), a Horizon Europe Cluster 2 Culture, creativity and inclusive society project and a representative of DG Communication – Citizens’ Dialogues unit.
More information and the registration link is available in the announcement on the MSCA website.
Programme in brief
12:30 - 12:45 Topic introduction
12:45 - 13:45 Discussion panel: the future of democracy
13:45 - 13:55 Policy reflections
13:55 - 14:00 Wrap up and announcement of next events
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
